Compare VSTA & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTA | TVGN |
|---|---|---|
| Founded | 1966 | 2020 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Blank Checks |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.2M | 89.6M |
| IPO Year | 2020 | N/A |
| Metric | VSTA | TVGN |
|---|---|---|
| Price | $4.97 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 9.6K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $326,007,430.00 | N/A |
| Revenue This Year | $11.22 | N/A |
| Revenue Next Year | $13.43 | N/A |
| P/E Ratio | $4.25 | ★ N/A |
| Revenue Growth | ★ 13.60 | N/A |
| 52 Week Low | $2.00 | $0.36 |
| 52 Week High | $5.49 | $1.92 |
| Indicator | VSTA | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 43.20 |
| Support Level | $4.91 | $0.37 |
| Resistance Level | $4.99 | $0.40 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 93.33 | 32.47 |
Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.